Sphere-9 Catheter Mapping and Ablation Catheter
Medtronic, Inc. · Decision date Aug 29, 2025
What did the FDA decide?
FDA records P240013/S015 as a supplement to PMA P240013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 29, 2025.
FDA approval order statement
the addition of a new wire management system in the tip sub-assembly process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 29, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240013/S015
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- Decision code
- OK30
- Decision date
- Aug 29, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240013 · Original PMA
Sphere-9 Catheter and Affera Ablation System
P240013/S012 · Related supplement
Sphere-9 Catheter and Affera Ablation System (HexaFlow Irrigation Pump; HexaGen RF Generator; HexaPulse PF Generator)
P240013/S014 · Related supplement
HexaFlow Irrigation Pumo AFR-00004, HexaGen TM RF Generator AFR-00005, HexaPulse TM PF Generator AFR-00008
P240013/S015 received
Application receipt date recorded by FDA.
P240013/S008 · Related supplement
AFR-00004 HexaGen RF Generator (RFG) and AFR-00008 HexaPulse PF Generator (PFG)
P240013/S013 · Related supplement
HexaGen RF Generator, HexaPulse PF Generator, HexaFlow Irrigation Pump
P240013/S015 · FDA decision
30-Day Notice
P240013/S010 · Related supplement
Sphere-9 Mapping and Ablation Catheter
P240013/S016 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S017 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S018 · Related supplement
Sphere-9 TM Mapping and Ablation Catheter
P240013/S019 · Related supplement
HexaGen RF Generator
P240013/S020 · Related supplement
Sphere-9 Catheter (AFR-00001)
P240013/S021 · Related supplement
Sphere-9 Catheter (AFR-00001)
P240013/S023 · Related supplement
Sphere-9 Catheter; Tubing Set; Extension Cable
P240013/S024 · Related supplement
Sphere-9 Catheter
P240013/S027 · Related supplement
Sphere-9 Mapping and Ablation Catheter; Tubing Set; Extension Cable
P240013/S025 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S022 · Related supplement
Affera Ablation System
P240013/S026 · Related supplement
HexaGen RF Generator Software and Remote
P240013/S029 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S030 · Related supplement
Sphere-9 Catheter AFR-00001
P240013/S031 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S028 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S032 · Related supplement
Affera Sphere-9 Mapping and Ablation Catheter
Timeline entries are records held by MedtechLedger for P240013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240013
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P240013/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



